<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821572</url>
  </required_header>
  <id_info>
    <org_study_id>BONNOTTE PARI 2013</org_study_id>
    <nct_id>NCT02821572</nct_id>
  </id_info>
  <brief_title>Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)</brief_title>
  <acronym>PTI Fc</acronym>
  <official_title>Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <brief_summary>
    <textblock>
      Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a peripheral&#xD;
      destruction of platelets responsible for bleedings.&#xD;
&#xD;
      Monocytes/macrophages play a double role by phagocyting platelets recognized by&#xD;
      autoantibodies and by maintaining the autoimmune response via their antigen-presenting cell&#xD;
      functions.&#xD;
&#xD;
      Fcgamma receptors (FcγR), that are represented by activating receptors (FcγRI, FcγRIIa,&#xD;
      FcγRIII) and an inhibiting one (FcγRIIb), are involved in the regulation of macrophages and&#xD;
      have been reported to be dysregulated in autoimmune diseases such as rheumatoid arthritis and&#xD;
      systemic lupus erythematous.&#xD;
&#xD;
      The aim of this study is to compare the expression of FcγR in patients with ITP on&#xD;
      circulating monocytes and on splenic macrophages.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2014</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1. The expressions of the activating FcγRs and the inhibiting receptor (FcγRIIb) on monocytes will be compared between ITP patients at diagnosis and controls - physiological parameter</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. The expressions of the activating FcγRs and the inhibiting receptor (FcγRIIb) on splenic macrophages will be compared between ITP patients and controls. - physiological parameter</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>patient</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>spleen sample</intervention_name>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>patient</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with ITP Persons without autoimmune disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ITP group&#xD;
&#xD;
          -  Patients who have provided written consent&#xD;
&#xD;
          -  Patients over 18 years&#xD;
&#xD;
          -  Patients with national health insurance&#xD;
&#xD;
          -  Patients with ITP, defined as thrombocytopenia &lt; 100 G/L, after exclusion of&#xD;
             infection- or drug-related thrombocytopenia and malignant hemopathy.&#xD;
&#xD;
        Control Group&#xD;
&#xD;
          -  Persons who have provided a written consent&#xD;
&#xD;
          -  Persons over 18 years&#xD;
&#xD;
          -  Persons with national health insurance&#xD;
&#xD;
          -  Persons without autoimmune disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under guardianship&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bernard BONNOTTE</last_name>
    <phone>3.80.29.34.32</phone>
    <phone_ext>33</phone_ext>
    <email>bernard.bonnotte@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard BONNOTTE</last_name>
      <phone>3.80.29.34.32</phone>
      <phone_ext>33</phone_ext>
      <email>bernard.bonnotte@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

